(Q35151142)
Statements
1 reference
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors (English)
1 reference
Patricia LoRusso
1 reference
Ratislav Bahleda
1 reference
Joanne Lager
1 reference
Li Liu
1 reference
Jason Jiang
1 reference
Jean-François Martini
1 reference
Sandrine Macé
1 reference
Howard Burris
1 reference
10 February 2015
1 reference
1 reference
20
1 reference
3
1 reference
245-246
1 reference
Identifiers
1 reference
1 reference
1 reference